A new regulatory switch for the oncoprotein c-Myc
A study published in PNAS resolves a central paradox in cancer cell biology concerning the degradation of the c-Myc oncoprotein. While the tumor suppressor PP2A is known to promote c-Myc degradation, its dephosphorylation of c-Myc at a specific site (Thr58) should, in theory, protect the protein from the primary degradation machinery, FBXW7. Researchers have now identified the PP2A-B55α protein phosphatase complex as the critical factor that switches c-Myc’s degradation pathway. When PP2A-B55α levels are high, it directs c-Myc towards a FBXW7-independent proteasomal degradation route. This discovery clarifies a key mechanism of post-translational modification and protein degradation that governs the stability of a major driver in cell cycle progression, gene expression regulation, and tumorigenesis.
Study Significance: This research provides a mechanistic blueprint for how cellular context dictates the fate of a central oncoprotein, offering a new lens for understanding tumor suppressor function in cancer cell biology. For professionals focused on cell signaling pathways like PI3K/AKT and mTOR, or those investigating targeted protein degradation therapies, these findings reveal a previously unknown regulatory node. It suggests that modulating specific PP2A complexes, rather than PP2A broadly, could be a more precise strategy for influencing c-Myc-driven cellular processes, from metabolism to proliferation.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
